Form D · Pharmaceuticals
FGH Biotech, Inc.
Houston, TX · CIK 0001657572
Offering snapshot reported May 22, 2018 · SEC filing
- Reported sold
- $2.08M Offering amount: $4M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $12.5K Reported outside-investor minimum
- First sale
- Oct 23, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 18
- Minimum accepted$0 → $12,500
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 22, 2018 | Amendment | $2,080,000 | No comparison | 18 | SEC filing |
| Sep 6, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 6, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-294133
Source: Form D, filed May 22, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lufti Abu Elheiga | Executive |
| Adam Kuspa | Director |
| Joe Wakil | Director, Executive |
| Salih J Wakil | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
414 Thamer Circle
Houston, TX, 77024
Houston, TX, 77024